Base de dados : MEDLINE
Pesquisa : D03.383.931.190 [Categoria DeCS]
Referências encontradas : 168 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 17 ir para página                         

  1 / 168 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
[PMID]:15163858
[Au] Autor:Kim HS; Austin J; Hage DS
[Ad] Endereço:Department of Chemistry, University of Nebraska, Lincoln, NE., USA.
[Ti] Título:Screening major binding sites on human serum albumin by affinity capillary electrophoresis.
[So] Source:Methods Mol Biol;276:169-87, 2004.
[Is] ISSN:1064-3745
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:A screening method is described for determining whether a drug or small solute has significant interactions at the two major binding sites on human serum albumin (HSA). This method uses affinity capillary electrophoresis (ACE) to perform a mobility shift assay, where the solute of interest is injected in both the presence of pH 7.4, 0.067 M phosphate buffer, and the same buffer containing a known concentration of HSA. Dextran is also used in the running buffer to adjust the mobility of HSA. Two types of modified HSA are used in this assay. The first is modified with 2-hydroxy-5-nitrobenzyl bromide (HNB), which selectively blocks HSA's warfarin-azapropazone site. The second type of HSA is modified with tetranitromethane (TNM), which decreases binding at the indole-benzodiazepine site. By comparing the mobility of a solute in the presence of these two modified forms of HSA vs normal HSA, it is possible to detect solute interactions at these binding sites. This approach is illustrated using warfarin and ibuprofen as examples of test solutes.
[Mh] Termos MeSH primário: 2-Hidroxi-5-nitrobenzil Brometo/química
Indóis/química
Albumina Sérica/química
Triptofano/química
Varfarina/química
[Mh] Termos MeSH secundário: Apazona/química
Benzodiazepinas/química
Eletroforese Capilar
Seres Humanos
Ibuprofeno/química
Ligação Proteica
Albumina Sérica/análise
Tetranitrometano/química
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, U.S. GOV'T, P.H.S.
[Nm] Nome de substância:
0 (Indoles); 0 (Serum Albumin); 12794-10-4 (Benzodiazepines); 5Q7ZVV76EI (Warfarin); 772-33-8 (2-Hydroxy-5-nitrobenzyl Bromide); 8724FJW4M5 (indole); 8DUH1N11BX (Tryptophan); K1G7CKU98F (Tetranitromethane); K2VOT966ZI (Apazone); WK2XYI10QM (Ibuprofen)
[Em] Mês de entrada:0409
[Cu] Atualização por classe:131121
[Lr] Data última revisão:
131121
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:040528
[St] Status:MEDLINE


  2 / 168 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:11208503
[Au] Autor:Géher P; Gömör B
[Ad] Endereço:Rheumatology and Physiotherapy, Semmelweis University of Medical Sciences, National Institute of Rheumatology and Physiotherapy, Budapest, Hungary.
[Ti] Título:Repeated cyclosporine therapy of peripheral arthritis associated with ankylosing spondylitis.
[So] Source:Med Sci Monit;7(1):105-7, 2001 Jan-Feb.
[Is] ISSN:1234-1010
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: A case history of a patient with ankylosing spondylitis and peripheral arthritis unresponsive to the conventional drug therapy, but successfully controlled by the use of cyclosporin. MATERIAL AND METHODS: In a 68 years old female patient with a 36 years history of typical ankylosing spondylitis a peripheral polyarthritis (hands, feet, wrists, and knees) developed. The patient did not suffer any other disease known to cause secondary spondylitis (psoriasis, inflammatory, bowel, disease). After the unsuccessful use of non-steroidal antiinflammatory drugs a combination therapy with cyclosporin (4 mg/kg/day) and azapropazone (300 mg t.i.d.) was introduced. RESULTS: Clinical improvement was achieved after 6 months of combined therapy, the polyarthritis completely resolved after one year. Therefore cyclosporin was discontinued. After one year the polyarthritis reappeared therefore the cyclosporin therapy was reinstituted with success. CONCLUSION: Cyclosporin has proved consistently effective in our case to control the peripheral arthritis associated with ankylosing spondylitis.
[Mh] Termos MeSH primário: Antirreumáticos/uso terapêutico
Artrite Reumatoide/tratamento farmacológico
Artrite/tratamento farmacológico
Ciclosporina/uso terapêutico
Espondilite Anquilosante/tratamento farmacológico
[Mh] Termos MeSH secundário: Idoso
Anti-Inflamatórios não Esteroides/uso terapêutico
Apazona/uso terapêutico
Artrite Reumatoide/complicações
Artrite Reumatoide/fisiopatologia
Dor nas Costas
Quimioterapia Combinada
Feminino
Seres Humanos
Dor
Espondilite Anquilosante/complicações
Espondilite Anquilosante/fisiopatologia
Resultado do Tratamento
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Anti-Inflammatory Agents, Non-Steroidal); 0 (Antirheumatic Agents); 83HN0GTJ6D (Cyclosporine); K2VOT966ZI (Apazone)
[Em] Mês de entrada:0108
[Cu] Atualização por classe:131121
[Lr] Data última revisão:
131121
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:010224
[St] Status:MEDLINE


  3 / 168 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:10796413
[Au] Autor:Saenz A; Ausejo M; Shea B; Wells G; Welch V; Tugwell P
[Ad] Endereço:Clinical Epidemiology Unit-C406, Loeb Research Institute, Ottawa Hospital-Civic Site, 1053 Carling Avenue, Ottawa, Ontario, Canada, K1Y 4E9. BSHEA@LRI.CA
[Ti] Título:Pharmacotherapy for Behcet's syndrome.
[So] Source:Cochrane Database Syst Rev;(2):CD001084, 2000.
[Is] ISSN:1469-493X
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:OBJECTIVES: To determine the effects of available pharmacological interventions in treating the different clinical features of Behcet's syndrome. SEARCH STRATEGY: We searched the Cochrane Musculoskeletal Group's trials register, the Cochrane Controlled Trials Register, and Medline up to January 1998. The computer search was complemented by a hand search of all bibliographic references from the reference lists of included trials. Principal investigators were contacted to seek unpublished literature. All languages were included. SELECTION CRITERIA: Studies were eligible if they fulfilled all of the four following criteria: 1. Randomized controlled trials, single or double-blind; 2. Participants were patients with Behcet's Syndrome as defined by the International Study Group, 1990 (Int Study Group, 1990); 3. Interventions included any pharmacological therapy compared to placebo or some other pharmacological intervention for the treatment of Behcet's syndrome. 4. Outcome measures included active ocular inflammatory processes, arthritis, mucocutaneous manifestations (oral ulcer, genital ulcer, erythema nodosum), laboratory changes and major events such as adverse effects and death. DATA COLLECTION AND ANALYSIS: The 32 potentially relevant references were assessed by two independent reviewers (MA, AS) according to the inclusion criteria. Ten trials fit the inclusion criteria and were included in this review. From the 10 included trials, data were independently extracted by the same two observers and crosschecked. The quality of the included trials was assessed independently by two observers (MA, AS) using a validated scale (Jadad 1996). For dichotomous measures, the treatment effect for each trial was calculated using a fixed effect model [Peto model (Petitti 1994)]. The weighted mean differences were based, if available, on end-of-trial results. The analysis was conducted separately for each different intervention. Since the trials could not be pooled it was not possible to carry out a sensitivity analysis by quality scores or a subgroup analysis by drug dosages. Because of this lack of comparability across trials and the small number of trials, we could not conduct a heterogeneity test or a funnel plot. MAIN RESULTS: Ten trials and 679 patients were included. The main results were the lack of efficacy of some of the classic treatments for Behcet's syndrome, including colchicine, cyclophosphamide and steroids for eye involvement, azapropazone and colchicine for arthritis and acyclovir, colchicine and topical interpheron for aphthas. The results confirm the protective effects of cyclosporine and azathioprine for eye involvement and benzathine-penicillin for arthritis. REVIEWER'S CONCLUSIONS: We conclude that further randomized, placebo-controlled, double-blind trials should be carried out to compare cyclosporine, azathioprine and benzathine-penicillin versus placebo in order to make the results generalizable and comparable.
[Mh] Termos MeSH primário: Síndrome de Behçet/tratamento farmacológico
[Mh] Termos MeSH secundário: Aciclovir/uso terapêutico
Anti-Infecciosos/uso terapêutico
Apazona/uso terapêutico
Azatioprina/uso terapêutico
Colchicina/uso terapêutico
Ciclosporina/uso terapêutico
Seres Humanos
Imunossupressores/uso terapêutico
Interferon-alfa/uso terapêutico
Penicilinas/uso terapêutico
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Anti-Infective Agents); 0 (Immunosuppressive Agents); 0 (Interferon-alpha); 0 (Penicillins); 83HN0GTJ6D (Cyclosporine); K2VOT966ZI (Apazone); MRK240IY2L (Azathioprine); SML2Y3J35T (Colchicine); X4HES1O11F (Acyclovir)
[Em] Mês de entrada:0007
[Cu] Atualização por classe:131121
[Lr] Data última revisão:
131121
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:000505
[St] Status:MEDLINE


  4 / 168 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:10485401
[Au] Autor:Gutgesell C; Fuchs T
[Ti] Título:Azapropazone in aspirin intolerance.
[So] Source:Allergy;54(8):897-8, 1999 Aug.
[Is] ISSN:0105-4538
[Cp] País de publicação:Denmark
[La] Idioma:eng
[Mh] Termos MeSH primário: Anti-Inflamatórios não Esteroides/efeitos adversos
Apazona/efeitos adversos
Aspirina/efeitos adversos
Hipersensibilidade a Drogas/diagnóstico
[Mh] Termos MeSH secundário: Hipersensibilidade a Drogas/etiologia
Seres Humanos
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Anti-Inflammatory Agents, Non-Steroidal); K2VOT966ZI (Apazone); R16CO5Y76E (Aspirin)
[Em] Mês de entrada:9910
[Cu] Atualização por classe:131121
[Lr] Data última revisão:
131121
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:990915
[St] Status:MEDLINE


  5 / 168 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:10329328
[Au] Autor:Lequesne MG
[Ad] Endereço:Hôpital Leopold Bellan, 31-33 rue Guilleminot, Paris, 75014, France.
[Ti] Título:Is there preliminary in-vivo evidences of an influence of nonsteroidal antiinflammatory drug treatment on osteoarthritis progression? Part I.
[So] Source:Osteoarthritis Cartilage;7(3):350, 1999 May.
[Is] ISSN:1063-4584
[Cp] País de publicação:England
[La] Idioma:eng
[Mh] Termos MeSH primário: Anti-Inflamatórios não Esteroides/efeitos adversos
Osteoartrite do Quadril/tratamento farmacológico
Osteoartrite do Joelho/tratamento farmacológico
[Mh] Termos MeSH secundário: Apazona/efeitos adversos
Progressão da Doença
Seres Humanos
Indometacina/efeitos adversos
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Anti-Inflammatory Agents, Non-Steroidal); K2VOT966ZI (Apazone); XXE1CET956 (Indomethacin)
[Em] Mês de entrada:0004
[Cu] Atualização por classe:161018
[Lr] Data última revisão:
161018
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:990518
[St] Status:MEDLINE


  6 / 168 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:9792509
[Au] Autor:Chattopadhyay A; Tian T; Kortum L; Hage DS
[Ad] Endereço:Chemistry Department, University of Nebraska, Lincoln 68588-0304, USA.
[Ti] Título:Development of tryptophan-modified human serum albumin columns for site-specific studies of drug-protein interactions by high-performance affinity chromatography.
[So] Source:J Chromatogr B Biomed Sci Appl;715(1):183-90, 1998 Sep 11.
[Is] ISSN:1387-2273
[Cp] País de publicação:Netherlands
[La] Idioma:eng
[Ab] Resumo:Human serum albumin (HSA) is one of the main proteins involved in the binding of drugs and small solutes in blood or serum. This study examined the changes in chromatographic properties that occur for immobilized HSA following the chemical modification of HSA's lone tryptophan residue (Trp-214). Trp-214 was reacted with o-nitrophenylsulfenyl chloride, followed by immobilization of the modified protein and normal HSA onto separate silica-based HPLC supports. The binding properties of the modified and normal HSA were then analyzed and compared by using frontal analysis and zonal elution experiments employing R/S-warfarin and L-tryptophan as probe compounds for the warfarin and indole binding regions of HSA. The modified HSA was found to have the same number of binding sites as normal HSA for R-warfarin and L-tryptophan but lower association equilibrium constants for these test solutes. Zonal elution studies with R- and S-warfarin on the modified HSA column demonstrated the importance of Trp-214 in determining the stereoselective binding of HSA for these agents. These studies also indicated that tryptophan modification can alter HSA-based separations for chiral solutes.
[Mh] Termos MeSH primário: Apazona/metabolismo
Cromatografia de Afinidade/métodos
Albumina Sérica/química
Triptofano/química
Varfarina/metabolismo
[Mh] Termos MeSH secundário: Seres Humanos
Ligação Proteica
Albumina Sérica/metabolismo
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, U.S. GOV'T, P.H.S.
[Nm] Nome de substância:
0 (Serum Albumin); 5Q7ZVV76EI (Warfarin); 8DUH1N11BX (Tryptophan); K2VOT966ZI (Apazone)
[Em] Mês de entrada:9812
[Cu] Atualização por classe:131121
[Lr] Data última revisão:
131121
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:981029
[St] Status:MEDLINE


  7 / 168 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:9430764
[Au] Autor:Rajaian H; Symonds HW; Bowmer CJ
[Ad] Endereço:Department of Pharmacology, University of Leeds, UK.
[Ti] Título:Drug binding sites on chicken albumin: a comparison to human albumin.
[So] Source:J Vet Pharmacol Ther;20(6):421-6, 1997 Dec.
[Is] ISSN:0140-7783
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:Mammalian albumins have two main structurally selective ligand binding sites. Site I binds drugs such as azapropazone, phenylbutazone and warfarin; whereas benzodiazepines, some dansyl amino acids, such as dansylsarcosine, and short chain fatty acids like octanoic acid interact with site II. However, it is not known if non-mammalian albumins have similar binding loci. In this study, drug binding sites on chicken albumin were investigated using site selective fluorescent probes (warfarin and dansylsarcosine) and p-nitrophenyl acetate (NPA); the hydrolysis of which is selectively inhibited by site II ligands. Azapropazone and phenylbutazone decreased the binding of warfarin and dansylsarcosine to a similar extent. Diazepam and octanoic acid also inhibited binding of the two fluorescent probes in a non-selective manner. However, the fluorescence intensity of the warfarin-chicken albumin complex decreased when the pH was increased from 6.0-9.0; but by contrast, the fluorescence of bound dansylsarcosine remained unchanged. Furthermore, the hydrolysis of NPA was selectively inhibited by dansylsarcosine, diazepam and octanoic acid (ligands selective for site II on mammalian albumins), but not by site I selective ligands such as azapropazone and warfarin. Overall, the results suggest that chicken albumin, like mammalian albumins, has discrete binding sites for warfarin and dansylsarcosine.
[Mh] Termos MeSH primário: Albuminas/metabolismo
Anticoagulantes/metabolismo
Sítios de Ligação
Compostos de Dansil/metabolismo
Sarcosina/análogos & derivados
Varfarina/metabolismo
[Mh] Termos MeSH secundário: Albuminas/química
Animais
Anti-Inflamatórios não Esteroides/farmacologia
Apazona/farmacologia
Sítios de Ligação/efeitos dos fármacos
Galinhas
Seres Humanos
Concentração de Íons de Hidrogênio
Hidrólise
Ligantes
Nitrofenóis/metabolismo
Sarcosina/metabolismo
Especificidade da Espécie
[Pt] Tipo de publicação:COMPARATIVE STUDY; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Albumins); 0 (Anti-Inflammatory Agents, Non-Steroidal); 0 (Anticoagulants); 0 (Dansyl Compounds); 0 (Ligands); 0 (Nitrophenols); 1093-96-5 (dansylsarcosine); 5Q7ZVV76EI (Warfarin); 830-03-5 (4-nitrophenyl acetate); K2VOT966ZI (Apazone); Z711V88R5F (Sarcosine)
[Em] Mês de entrada:9801
[Cu] Atualização por classe:131121
[Lr] Data última revisão:
131121
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:980207
[St] Status:MEDLINE


  8 / 168 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:8846748
[Au] Autor:Pini LA; Sandrini M; Vitale G
[Ad] Endereço:Clinical Pharmacology Unit, University of Modena, Italy.
[Ti] Título:Lack of activity of azapropazone in the hot-plate test and in 5-HT1A and 5-HT2 receptor subtypes in rat brain membranes.
[So] Source:Drugs Exp Clin Res;21(5):181-6, 1995.
[Is] ISSN:0378-6501
[Cp] País de publicação:Switzerland
[La] Idioma:eng
[Ab] Resumo:This study aimed to investigate the antinociceptive activity of azapropazone (AZA), a weak prostaglandin synthesis inhibitor using the hot-plate test, and its ability to modify the serotonin-binding capacity in rat brain membranes. It revealed that AZA had no antinociceptive effect in the hot-plate test at the doses of 400 and 600 mg/kg when orally administered (p.o.), and at 400, 500 and 600 mg/kg after intraperitoneal injection (i.p.). At the dose of 600 mg/kg i.p. the drug failed to modify the number and the affinity of 5-HT1A and 5-HT2 receptors in rat brain membranes. In accordance with our previous findings on a positive correlation between NSAIDs antinociception in this experimental model and changes in 5-HT receptor characteristics, these results suggest an association between the lack of AZA-mediated antinociception in the hot-plate test and the drug's inability to modify the characteristics of 5-HT1A and 5-HT2 receptor binding sites in rat brain membranes.
[Mh] Termos MeSH primário: Analgésicos/farmacologia
Anti-Inflamatórios não Esteroides/farmacologia
Apazona/farmacologia
Química Encefálica/efeitos dos fármacos
Receptores de Serotonina/efeitos dos fármacos
[Mh] Termos MeSH secundário: 8-Hidroxi-2-(di-n-propilamino)tetralina/farmacocinética
Animais
Anti-Inflamatórios não Esteroides/farmacocinética
Apazona/farmacocinética
Ligação Competitiva/efeitos dos fármacos
Ketanserina/farmacocinética
Masculino
Membranas/efeitos dos fármacos
Membranas/metabolismo
Atividade Motora/efeitos dos fármacos
Medição da Dor/efeitos dos fármacos
Ratos
Ratos Wistar
Antagonistas da Serotonina/farmacocinética
Agonistas de Receptores de Serotonina/farmacologia
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Analgesics); 0 (Anti-Inflammatory Agents, Non-Steroidal); 0 (Receptors, Serotonin); 0 (Serotonin Antagonists); 0 (Serotonin Receptor Agonists); 78950-78-4 (8-Hydroxy-2-(di-n-propylamino)tetralin); 97F9DE4CT4 (Ketanserin); K2VOT966ZI (Apazone)
[Em] Mês de entrada:9610
[Cu] Atualização por classe:131121
[Lr] Data última revisão:
131121
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:950101
[St] Status:MEDLINE


  9 / 168 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
PubMed Central Texto completo
[PMID]:8703660
[Au] Autor:Lötsch J; Mohammadian P; Hummel T; Florin S; Brune K; Geisslinger G; Kobal G
[Ad] Endereço:Department of Experimental and Clinical Pharmacology and Toxicology, University of Erlangen-Nürnberg, Germany.
[Ti] Título:Effects of azapropazone on pain-related brain activity in human subjects.
[So] Source:Br J Clin Pharmacol;40(6):545-52, 1995 Dec.
[Is] ISSN:0306-5251
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:1. The dose-related effects of azapropazone on (i) event-related and spontaneous EEG-activity and (ii) the subjects' pain ratings were investigated using an experimental human pain model based on both chemo-somatosensory event-related potentials (CSSERP) and subjects' pain ratings. 2. Healthy subjects (n = 20) participated in a placebo-controlled, randomized, double-blind, four-way cross-over study. Single doses of azapropazone (300 mg, 600 mg and 1200 mg) and placebo were administered intravenously. Each experiment consisted of five sessions (before and 1, 2, 4 and 8 h after administration of the medication). Each session lasted for approximately 40 min. In the first 20 min, pain was induced by short CO2-stimuli presented to the right nostril (phasic pain; interstimulus interval 30 s) and EEG was recorded from five positions. CSSERPs were obtained in response to painful CO2-stimuli. In the following 20 min period, tonic pain was induced by a constant stream of dry air introduced in the left nostril. Subjects rated the intensity of both phasic and tonic pain by means of a visual analogue scale. Additionally, a frequency analysis of the spontaneous EEG was performed. 3. Azapropazone reduced the pain-related CSSERP-amplitudes at frontal and parietal recording positions. This topographical pattern was observed in previous studies with opioids, while NSAIDs such as flurbiprofen and ketoprofen exerted effects at frontal and central positions. In contrast to other NSAIDs, administration of azapropazone resulted in a reduction of the frequency bands alpha 1, delta and theta of the spontaneous EEG. At the subjective level, analgesic effects of azapropazone were observed in the ratings of tonic pain. 4. Analgesic properties of azapropazone were demonstrated in man. The topographical pattern of the changes in the CSSERPs and the effects on EEG background activity suggest a central component of the analgesic action of azapropazone.
[Mh] Termos MeSH primário: Anti-Inflamatórios não Esteroides/farmacologia
Apazona/farmacologia
Eletroencefalografia/efeitos dos fármacos
Dor/fisiopatologia
[Mh] Termos MeSH secundário: Adulto
Anti-Inflamatórios não Esteroides/administração & dosagem
Apazona/administração & dosagem
Estudos Cross-Over
Método Duplo-Cego
Potenciais Somatossensoriais Evocados
Feminino
Seres Humanos
Masculino
Medição da Dor/efeitos dos fármacos
[Pt] Tipo de publicação:CLINICAL TRIAL; JOURNAL ARTICLE; RANDOMIZED CONTROLLED TRIAL; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Anti-Inflammatory Agents, Non-Steroidal); K2VOT966ZI (Apazone)
[Em] Mês de entrada:9609
[Cu] Atualização por classe:131121
[Lr] Data última revisão:
131121
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:951201
[St] Status:MEDLINE


  10 / 168 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
[PMID]:7586783
[Au] Autor:Moral F; Hamuryudan V; Yurdakul S; Yazici H
[Ad] Endereço:Division of Rheumatology, Cerrahpasa Medical Faculty, University of Istanbul, Turkey.
[Ti] Título:Inefficacy of azapropazone in the acute arthritis of Behçet's syndrome: a randomized, double blind, placebo controlled study.
[So] Source:Clin Exp Rheumatol;13(4):493-5, 1995 Jul-Aug.
[Is] ISSN:0392-856X
[Cp] País de publicação:Italy
[La] Idioma:eng
[Ab] Resumo:Sixty-three consecutive Behçet's syndrome patients with an acute arthritis of up to 10 days duration were treated either with azapropazone (APZ) 300 mg t.i.d. or placebo for three weeks. Twenty-eight patients (14 males, 14 females: mean age 36.2 +/- 8.1 SD years) from the APZ group and 29 patients (18 males, 11 females; mean age 34.2 +/- 8.4 SD years) from the placebo group completed the trial. At the end of the trial the arthritis persisted in 53.5% (15/28) of the APZ patients and in 41.3% (12/29) of the placebo patients (chi 2 = 0.85; NS). Six patients (6/28; 21%) from the APZ group and 9 patients (9/29; 31%) from the placebo group developed new joint involvement (chi 2 = 0.7; NS). There was no difference in the duration of arthritis between the two groups (19.9 +/- 8.3 SD days in the APZ groups vs. 19.7 +/- 8.2 SD days in the placebo group; NS). The degree of joint swelling, the tender joint score and the visual analogue score for pain significantly improved in both groups, but there was no difference in any of these parameters between the groups except for a significant difference in the visual analogue score for less pain at the first week in the azapropazone group (t = 2.23; p < 0.05). There were also no differences in the mean numbers of acetaminophen tablets used or in the CRP and ESR levels between the two groups. We conclude that azapropazone is not effective in controlling the arthritis of Behçet's syndrome.
[Mh] Termos MeSH primário: Apazona/uso terapêutico
Artrite/complicações
Artrite/tratamento farmacológico
Síndrome de Behçet/complicações
[Mh] Termos MeSH secundário: Doença Aguda
Adulto
Apazona/efeitos adversos
Artrite/fisiopatologia
Método Duplo-Cego
Feminino
Seres Humanos
Masculino
Cuidados Paliativos
Placebos
Falha de Tratamento
[Pt] Tipo de publicação:CLINICAL TRIAL; JOURNAL ARTICLE; RANDOMIZED CONTROLLED TRIAL
[Nm] Nome de substância:
0 (Placebos); K2VOT966ZI (Apazone)
[Em] Mês de entrada:9512
[Cu] Atualização por classe:170112
[Lr] Data última revisão:
170112
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:950701
[St] Status:MEDLINE



página 1 de 17 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde